



HAL
open science

Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis

Amalia Colalillo, Eric Hachulla, Chiara Pellicano, Vanessa Smith, Christina Bergmann, Gabriela Riemekasten, Elisabetta Zanatta, Jörg Henes, David Launay, Antonella Marcocchia, et al.

► **To cite this version:**

Amalia Colalillo, Eric Hachulla, Chiara Pellicano, Vanessa Smith, Christina Bergmann, et al.. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis. *Chest*, 2024, *Chest*, Online ahead of print. 10.1016/j.chest.2024.05.010 . hal-04682691

HAL Id: hal-04682691

<https://hal.univ-lille.fr/hal-04682691v1>

Submitted on 30 Aug 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis

Q16 Q1 Amalia Colalillo, MD; Eric Hachulla, MD, PhD; Chiara Pellicano, MD; Vanessa Smith, MD, PhD; Christina Bergmann, MD; Gabriela Riemekasten, MD, PhD; Elisabetta Zanatta, MD, PhD; Jörg Henes, MD, PhD; David Launay, MD, PhD; Antonella Marcocchia, MD; Ana Maria Gheorghiu, MD, PhD; Marie-Elise Truchetet, MD, PhD; Florenzo Iannone, MD, PhD; Carmen Pilar Simeón Aznar, MD, PhD; Susana Oliveira, MD; Madelon Vonk, MD, PhD; Francesco Del Galdo, MD, PhD; and Edoardo Rosato, MD, PhD; for the EUSTAR Collaborators*

BACKGROUND: The 2022 European Society of Cardiology/European Respiratory Society guidelines define pulmonary hypertension (PH) as a resting mean pulmonary artery pressure (mPAP) > 20 mm Hg at right heart catheterization (RHC). Previously, patients with an mPAP between 21 and 24 mm Hg were classified in a “gray zone” of unclear clinical significance.

RESEARCH QUESTION: What is the diagnostic performance of the main parameters used for PH screening in detecting patients with systemic sclerosis (SSc) with an mPAP of 21 to 24 mm Hg at RHC?

STUDY DESIGN AND METHODS: Patients with SSc from the European Scleroderma Trials and Research (EUSTAR) database with available tricuspid annular plane systolic excursion (TAPSE), systolic PAP (sPAP), and mPAP data were included. Patients with mPAP 21 to 24 mm Hg and patients with mPAP ≤ 20 mm Hg were considered for the analysis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated.

RESULTS: TAPSE/sPAP was lower in the group of patients with SSc with mPAP 21 to 24 mm Hg than in the non-PH group (0.58 [0.46-0.72] vs 0.69 [0.57-0.81] mm/mm Hg, respectively; $P < .01$). No difference was found in other parameters between the two groups. Diffusing capacity of the lungs for carbon monoxide (DLCO) < 80% of the predicted value had the highest sensitivity (88.9%) and NPV (80%), but the lowest specificity (18.2%) and PPV (30.8%) in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity (78.9%), PPV (50%), and accuracy (68.1%); its NPV was 75.4%, and its sensitivity was 45.1%.

INTERPRETATION: DLCO < 80% of the predicted value is the parameter with the highest sensitivity and NPV in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg has the highest specificity, PPV, and accuracy and, therefore, can be a useful additional parameter to decrease the number of unnecessary RHCs.

CHEST 2024; ■(■):■-■

KEY WORDS: diffusing capacity of the lungs for carbon monoxide; pulmonary hypertension; screening; systemic sclerosis; tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure

Take-home Points

Study Question: What is the diagnostic performance of the main parameters used for PH screening in detecting patients with systemic sclerosis (SSc) with a mean pulmonary arterial pressure (mPAP) of 21 to 24 mm Hg at right heart catheterization?

Results: Diffusing capacity of the lungs for carbon monoxide (DLCO) < 80% of the predicted value is the parameter with the highest sensitivity and negative predictive value in detecting patients with SSc with mPAP 21 to 24 mm Hg, whereas a TAPSE/sPAP (tricuspid annular plane systolic excursion/systolic PAP) ratio < 0.55 mm/mm Hg has the highest specificity, positive predictive value, and accuracy.

Interpretation: DLCO < 80% of the predicted value identifies most patients with SSc with mPAP 21 to 24 mm Hg, whereas TAPSE/sPAP ratio < 0.55 mm/mm Hg can be a useful additional parameter to decrease the number of unnecessary right heart catheterizations.

For many years pulmonary hypertension (PH) has been defined as a mean pulmonary arterial pressure (mPAP) \geq 25 mm Hg at rest measured invasively by right heart catheterization (RHC).¹ Normal mPAP at rest is 14 ± 3 mm Hg with an upper limit of 20 mm Hg. Thus, patients with an mPAP between 21 and 24 mm Hg were classified in a “gray zone” of unclear clinical significance.¹ Subsequent studies have shown a significant increase in mortality and hospitalization risk with mPAP

> 20 mm Hg.^{2,3} The 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines define PH as a resting mPAP > 20 mm Hg at RHC.⁴ PH in patients with systemic sclerosis (SSc) may also be caused by left heart diseases (group 2) and lung diseases (group 3).⁴

Several screening tools are available to guide patient selection for RHC referral to confirm PH diagnosis in patients with SSc. Resting echocardiography remains the most common screening tool used for early detection of PH, both as a single measure or as part of a composite measure.⁵ Tricuspid regurgitation velocity (TRV) or estimated systolic pulmonary artery pressure (sPAP) are the key variables for assigning the echocardiographic probability of PH.⁴ In the current PH guidelines, the tricuspid annular plane systolic excursion (TAPSE)/sPAP ratio has been included for the first time among the additional echocardiographic signs suggestive of PH.⁴ Moreover, it has recently been shown that a reduced TAPSE/sPAP ratio is a predictive risk factor for PH in patients with SSc.⁶ An isolated reduced diffusing capacity of the lungs for carbon monoxide (DLCO) and in particular an isolated reduced DLCO with a relatively preserved FVC is associated with SSc-PH.⁷⁻¹⁰ Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP)⁹⁻¹¹ and serum urate levels⁹ have also been associated with a higher risk of PH in patients with SSc.

However, to date, and to the best of our knowledge, there are no studies specifically investigating the performance of the existing PH screening tools in detecting patients with SSc with an mPAP of 21 to 24 mm Hg.

ABBREVIATIONS: DLCO = diffusing capacity of the lungs for carbon monoxide; ERS = European Respiratory Society; ESC = European Society of Cardiology; EUSTAR = European Scleroderma Trials and Research Group; IQR = interquartile range; mPAP = mean pulmonary arterial pressure; NPV = negative predictive value; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PFT = pulmonary function test; PH = pulmonary hypertension; PPV = positive predictive value; RHC = right heart catheterization; sPAP = systolic pulmonary arterial pressure; SSc = systemic sclerosis; TAPSE = tricuspid annular plane systolic excursion; TRV = tricuspid regurgitation velocity

AFFILIATIONS: From the Department of Translational and Precision Medicine (A. C., C. P., and E. R.), Sapienza University of Rome, Rome, Italy; the University of Lille (E. H. and D. L.), INSERM, CHU Lille, Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, CERAINOM, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France; the Department of Internal Medicine and Department of Rheumatology (V. S.), Ghent University Hospital, and the Unit for Molecular Immunology and Inflammation (V. S.), VIB Inflammation Research Center (IRC), Ghent, Belgium; the Department of Internal Medicine (C. B.), University Hospital Erlangen, Erlangen, Germany; the Department of Rheumatology and Clinical Immunology (G. R.), University of Lübeck, Lübeck, Germany; the Rheumatology Unit (E. Z.), Padova University Hospital, Padua, Italy; the Center for Interdisciplinary Rheumatology,

Auto-inflammatory Diseases and Internal Medicine (J. H.), University Hospital Tübingen, Tübingen, Germany; the Centro di Riferimento Interdisciplinare (A. M.), Interdipartimentale per la Diagnosi Precoce della Sclerodermia (CRIIS), Sandro Pertini Hospital, Rome, Italy; the Carol Davila University on Medicine and Pharmacy, Internal Medicine and Rheumatology Department (A. M. G.), Cantacuzino Hospital, Bucharest, Romania; the Department of Rheumatology (M.-E. T.), CHU de Bordeaux, Bordeaux, France; the Rheumatology Unit (F. I.), University of Bari, Bari, Italy; the Unit of Autoimmune Diseases, Department of Internal Medicine (C. P. S. A.), Hospital Universitario Vall d'Hebron, Barcelona, Spain; the Systemic Immunomediated Diseases Unit, Department of Medicine (S. O.), Amadora, Portugal; the Department of Rheumatology (M. V.), Radboud University Medical Center, Nijmegen, The Netherlands; and the Leeds Raynaud's and Scleroderma Program (F. D. G.), NIHR Biomedical Research Centre Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, England. *Collaborators from EUSTAR are listed in the Acknowledgment.

CORRESPONDENCE TO: Edoardo Rosato, MD, PhD; email: edoardo.rosato@uniroma1.it

Copyright © 2024 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

DOI: <https://doi.org/10.1016/j.chest.2024.05.010>

The aim of this study was to compare the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of the main echocardiographic, pulmonary function test (PFT), and

laboratory parameters for PH screening in the European Scleroderma Trials and Research Group (EUSTAR) cohort of patients with SSc with mPAP 21 to 24 mm Hg.

Study Design and Methods

Study Design and Inclusion Criteria

This was an observational cross-sectional study of data collected from the multinational EUSTAR database. The structure of the online database, the collected data set, and definitions of clinical variables have been previously reported in detail.^{12,13}

Inclusion criteria were as follows: (1) registration in the EUSTAR database since 2010 (start of the online version), (2) age \geq 18 years, (3) fulfillment of the 2013 American College of Rheumatology/European League Against Rheumatism SSc classification criteria,¹⁴ (4) availability of TAPSE and sPAP measurements on echocardiography, and (5) availability of RHC data (mPAP). The TAPSE/sPAP ratio was calculated for all patients with SSc included. PH was defined as mPAP $>$ 20 mm Hg.⁴ Among patients included were identified three groups based on RHC data: (1) patients with mPAP \leq 20 mm Hg (PH diagnosis excluded), (2) patients with mPAP 21 to 24 mm Hg, and (3) patients with mPAP \geq 25 mm Hg. Only group 1 and group 2 were considered for the analysis.

Statistical Analysis

Statistical analysis was performed with SPSS Statistics version 26 (IBM). In this study, our objective was to ascertain the diagnostic sensitivity, with an anticipated threshold of 0.9. Given a prevalence of PH of 0.15 and aiming for a precision of 0.1 within the 95% CI, we calculated the optimal sample size to be 231 participants. Taking into account a dropout rate of 5% to 10%, we adjusted the anticipated sample size, resulting in a final cohort of 250 participants. The Shapiro-Wilk test was used to evaluate the normal distribution of data.

Categorical data are represented as frequencies and proportions. Continuous variables are reported as median and interquartile range (IQR). Nonparametric tests were

used to evaluate statistical differences because data for some variables (sPAP, DLCO, NT-proBNP, FVC/DLCO, serum urate) are not normally distributed. TAPSE/sPAP, FVC, and TAPSE are normally distributed. The Mann-Whitney test was used to assess differences between continuous variables. The Fisher exact test was used to evaluate the difference between categorical variables. Sensitivity, specificity, PPV, and NPV, and accuracy of echocardiographic, PFT, and laboratory parameters were calculated to assess the diagnostic performance of these items in identifying patients with SSc with mPAP 21 to 24 mm Hg. Parameters included in the analysis were as follows: sPAP $>$ 36 mm Hg,^{4,14} TAPSE/sPAP $<$ 0.55 mm/mm Hg,^{4,5} DLCO $<$ 80% of the predicted value, DLCO $<$ 60% of the predicted value, FVC/DLCO \geq 1.82,⁹ NT-proBNP \geq 125 pg/mL,¹⁵ NT-proBNP \geq 210 pg/mL,⁹ serum urate \geq 6 mg/dL. Sensitivity was calculated as the number of true positives/(number of true positives + number of false negatives); specificity was calculated as the number of true negatives/(number of true negatives + number of false positives); PPV was calculated as the number of true positives/(number of true positives + number of false positives); NPV was calculated as the number of true negatives/(number of true negatives + number of false negatives). Accuracy was calculated as (number of true positives + number of true negatives)/(number of true positives + number of true negatives + number of false positives + number of false negatives). Listwise deletion was done to handle missing data. Moreover, the multivariate imputation by chained equations was used to handle missing data (we used the function mice of the R package mice). Receiver operating characteristic curves were used to evaluate the diagnostic performance of sPAP, TAPSE/sPAP ratio, DLCO, FVC/DLCO, NT-proBNP, and serum urate. A significance level of .05 was used for all tests.

Results

From the EUSTAR database, 355 patients with SSc met the inclusion criteria for this study. Of these, 109 patients with SSc had mPAP \leq 20 mm Hg, 51 patients with SSc had mPAP 21 to 24 mm Hg, and 195 patients with SSc had mPAP \geq 25 mm Hg.

Demographic and clinical characteristics of the 51 patients with SSc with mPAP 21 to 24 mm Hg and of the 109 patients with mPAP \leq 20 mm Hg are shown in [Table 1](#). None of the patients were treated with colchicine or xanthine oxidase inhibitors. RHC parameters and PH group classification of the 51

TABLE 1] Demographic and Clinical Characteristics of Patients With SSc With PH Confirmed by Right Heart Catheterization (mPAP, 21-24 mm Hg) and Patients With SSc With PH Not Confirmed by Right Heart Catheterization (mPAP, \leq 20 mm Hg)

Characteristic	Patients with mPAP 21-24 mm Hg (n = 51)		Patients with mPAP \leq 20 mm Hg (n = 109)		P Value
	Results	No.	Results	No.	
Age, median (IQR), y	69 (63-75)	51	67 (61-75)	109	.218
Male, No. (%)	9 (17.6)	51	24 (22)	109	.676
Disease duration, median (IQR), y	12 (8-22)	39	12 (9-18)	92	.559
lcSSc, No. (%)	27 (73)	37	48 (58.5)	82	.154
ACA, No. (%)	19 (46.3)	41	32 (41.6)	77	.839
ATA, No. (%)	14 (32.6)	43	30 (38)	79	.543
ARA, No. (%)	3 (9.4)	32	0 (0)	58	< .05
mRSS, median (IQR)	3 (0-10)	33	7 (2-13)	73	< .05
Digital ulcer history, No. (%)	18 (43.9)	41	49 (50.5)	97	.585
Telangiectasia, No. (%)	29 (61.7)	47	72 (74.2)	97	.079
NYHA class, No. (%)					
I	12 (25.5)	47	27 (27.6)	98	.846
II	23 (48.9)	47	45 (45.9)	98	
III	10 (21.3)	47	24 (24.5)	98	
IV	2 (4.3)	47	2 (2)	98	
NT-proBNP, median (IQR), pg/mL	286 (97-805)	27	247 (111-532)	48	.691
NT-proBNP \geq 125 pg/mL, No. (%)	16 (59.3)	27	34 (71)	48	.321
NT-proBNP \geq 210 pg/mL, No. (%)	14 (51.9)	27	27 (56.2)	48	.810
Serum urate, median (IQR), mg/dL	5.5 (4.1-6.4)	27	4.9 (4.3-6.2)	47	.649
Serum urate \geq 6 mg/dL, No. (%)	9 (33.3)	27	13 (27.7)	47	.599
FVC, % predicted, median (IQR)	88 (74-109)	44	95 (76-110)	94	.281
DLco, % predicted, median (IQR)	48 (43-66)	40	61 (45-76)	88	.150
DLco < 80% predicted, No. (%)	32 (80)	40	72 (81.8)	88	.426
DLco < 60% predicted, No. (%)	22 (55)	40	43 (48.9)	88	.240
FVC/DLco, median (IQR)	1.69 (1.35-2.09)	40	1.54 (1.32-2)	87	.358
FVC/DLco \geq 1.82, No. (%)	13 (32.5)	40	26 (29.9)	87	.528
LVEF, %, median (IQR)	61 (55-66)	43	60 (57-65)	94	.993
Right atrium area, median (IQR), cm ²	16.4 (14.9-17.1)	10	15.8 (13-17)	18	.408
TAPSE, median (IQR), mm	20 (18-24)	51	23 (20-25)	109	< .01
sPAP, median (IQR), mm Hg	35 (30-45)	51	31 (28-40)	109	.070
sPAP > 36 mm Hg, No. (%)	21 (41.2)	51	41 (37.6)	109	.729
TAPSE/sPAP, median (IQR), mm/mm Hg	0.58 (0.46-0.72)	51	0.69 (0.57-0.81)	109	< .01
TAPSE/sPAP < 0.55 mm/mm Hg, No. (%)	23 (45.1)	51	23 (21.1)	109	< .01
Serum creatinine, mg/dL	0.78 (0.71-0.90)	51	0.80 (0.80-0.90)	109	> .05

Percentages are calculated on the number of available data (n = number of patients with available data). ACA = anti-centromere antibodies; ARA = anti-RNA polymerase III antibodies; ATA = anti-topoisomerase I antibodies; DLco = diffusing capacity of the lungs for carbon monoxide; IQR = interquartile range; lcSSc = limited cutaneous SSc; LVEF = left ventricular ejection fraction; mPAP = mean pulmonary artery pressure; mRSS = modified Rodnan skin score; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association; PH = pulmonary hypertension; sPAP = systolic pulmonary arterial pressure; SSc = systemic sclerosis; TAPSE = tricuspid annular plane systolic excursion.

patients with SSc with mPAP 21 to 24 mm Hg are reported in [Table 2](#).

The TAPSE/sPAP ratio was significantly lower in patients with SSc with mPAP 21 to 24 mm Hg than in

patients with SSc with mPAP \leq 20 mm Hg (0.58 [0.46-0.72] vs 0.69 [0.57-0.81] mm/mm Hg; $P < .01$). No difference was found in sPAP, right atrium area, DLco, FVC/DLco, NT-proBNP, and serum urate between

TABLE 2] Right Heart Catheterization Parameters of 51 Patients With Systemic Sclerosis With mPAP 21 to 24 mm Hg

Parameter	Results	No.
mPAP, mm Hg	22 (21-23)	51
PAWP, mm Hg	11 (8-12)	43
PVR, WU	2.8 (1.9-3.6)	28
CO, L/min	5.3 (4.3-6.2)	29
CI, L/min/m ²	3.3 (2.6-3.8)	41
Group 1 or 3 PH	17 (65.4)	26
Group 2 PH	0	26
Unclassified PH ^a	9 (34.6)	26

Values are expressed as median and interquartile range (IQR) or as number and percentage (%). Percentages are calculated on the number of available data (No. = number of patients with available data). CI = cardiac index; CO = cardiac output; mPAP = mean pulmonary artery pressure; PAWP = pulmonary arterial wedge pressure; PH = pulmonary hypertension; PVR = pulmonary vascular resistance; WU = Wood units.

^aPatients with elevated mPAP (> 20 mm Hg) but low PVR (\leq 2 WU) and PAWP (\leq 15 mm Hg).

patients with SSc with mPAP 21 to 24 mm Hg and the non-PH group.

The receiver operating characteristic curve analysis showed an area under the curve of 0.653 (0.562-0.745; $P < .01$) for the TAPSE/sPAP ratio, 0.589 (0.492-0.686; $P > .05$) for sPAP, 0.583 (0.475-0.690; $P > .05$) for DLCO, 0.447 (0.337-0.557; $P > .05$) for FVC/DLCO, 0.528 (0.384-0.672; $P > .05$) for NT-proBNP, and 0.532 (0.391-0.674; $P > .05$) for serum urate.

TAPSE/sPAP ratio < 0.55 mm/mm Hg was the parameter with the highest specificity (78.9%) and PPV (50%) in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP ratio < 0.55 mm/mm Hg NPV was 75.4%. TAPSE/sPAP ratio < 0.55 mm/mm Hg had higher sensitivity, specificity, PPV, and NPV compared with sPAP > 36 mm Hg. DLCO < 80% of the predicted value was the parameter with the highest sensitivity (88.9%) and NPV (80%), but with the lowest specificity (18.2%) and PPV (30.8%). FVC/DLCO \geq 1.82 had a specificity of 70.1% and an NPV of 72.6%, but low sensitivity (36.1%) and PPV (33.3%). NT-proBNP \geq 210 pg/mL had a sensitivity, specificity, PPV, and NPV of 51.9%, 43.8%, 34.1%, 61.8%, respectively. Serum urate \geq 6 mg/dL had a sensitivity, specificity, PPV, and NPV of 34.6%, 72.3%, 40.9%, and 66.7%, respectively. TAPSE/sPAP ratio < 0.55 mm/mm Hg was the parameter with the highest accuracy (68.1%). Sensitivity, specificity, PPV, and NPV, and accuracy of echocardiographic, PFT, and laboratory parameters for PH screening in patients with SSc, are shown in Table 3.

Discussion

In this study, a DLCO < 80% of the predicted value showed the highest sensitivity and NPV in identifying patients with mPAP 21 to 24 mm Hg, whereas the parameter with the highest specificity and PPV was a TAPSE/sPAP ratio < 0.55 mm/mm Hg. Moreover, a TAPSE/sPAP ratio < 0.55 showed the highest accuracy among the considered parameters.

Previous guidelines defined PH as a resting mPAP \geq 25 mm Hg measured by RHC and included patients with mPAP 21 to 24 mm Hg in a so-called “gray zone” of unclear clinical significance. Patients presenting with an mPAP in this range needed to be carefully monitored when they were at risk for developing PH, for example, patients with connective tissue disease.¹ The 2022 ESC/ERS guidelines removed this gray area and defined PH as a resting mPAP > 20 mm Hg, supporting the prognostic relevance of identifying patients with PH earlier in the preclinical disease course.⁴ Available PH screening tools in patients with SSc have been widely validated on the previous definition of PH. To date, there are no studies on the diagnostic performance of the existing PH screening parameters in detecting patients with SSc with mPAP 21 to 24 mm Hg.

Our results show that most of the patients with SSc with mPAP 21 to 24 mm Hg had a DLCO < 80% of the predicted value, less than one-half had an increased sPAP, and none of them had an increased right atrial area (RAA) > 18 cm². Despite the missing data, the RAA does not seem to be a reliable measure in identifying patients with SSc with mPAP 21 to 24 mm Hg. RAA is the echocardiographic parameter included in the DETECT algorithm in association with TRV to select patients for RHC referral.⁹ TAPSE/sPAP ratio was the only parameter showing a significant difference between patients with SSc with mPAP 21 to 24 mm Hg and patients with SSc without PH.

In this study, the probability of a DLCO < 80% of the predicted value identifying patients with SSc with mPAP 21 to 24 mm Hg was 88.9%. However, the probability of a DLCO > 80% predicted correctly identifying non-PH participants was only 18.1%. A high sensitivity is usually desired in a screening test, because when sensitivity increases the number of patients with preclinical disease not diagnosed by the test decreases. Therefore, sensitivity is usually increased at the expense of specificity when the disease is serious and curable in its preclinical phase. However, a test with an extremely low specificity produces a high percentage of erroneously

TABLE 3] Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, and Accuracy of Echocardiographic, Pulmonary Function Tests and Laboratory Parameters for Pulmonary Hypertension Screening of Patients with Systemic Sclerosis With mPAP 21 to 24 mm Hg With Listwise Deletion and Multiple Imputation

Parameter	Listwise Deletion						Multivariate Imputation					
	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Accuracy (%)		Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Accuracy (%)	
sPAP > 36 mm Hg	41.2	62.4	33.9	69.4	55.6		NA	NA	NA	NA	NA	
TAPSE/sPAP < 0.55 mm/mm Hg	45.1	78.9	50	75.4	68.1		NA	NA	NA	NA	NA	
Dlco < 80% predicted	88.9	18.2	30.8	80	38.7		89.8	18.3	34	42.1	41.1	
Dlco < 60% predicted	61.1	51.1	33.8	76.3	54		61.6	49.9	36.5	42.2	53.6	
FVC/Dlco ≥ 1.82	36.1	70.1	33.3	72.6	60.2		35.3	69.4	35	40.5	58.5	
NT-proBNP ≥ 125 pg/mL	59.3	29.2	32	56	40		65.1	33.4	31.4	37.5	43.5	
NT-proBNP ≥ 210 pg/mL	51.9	43.8	34.1	61.8	46.7		58	45	33.1	39	49.1	
Serum urate ≥ 6 mg/dL	34.6	72.3	40.9	66.7	58.9		35.7	71.2	37.1	42.2	59.9	

Dlco = diffusing capacity of the lungs for carbon monoxide; mPAP = mean pulmonary artery pressure; NA = XXX; NPV = negative predictive value; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PPV = positive predictive value; sPAP = systolic pulmonary arterial pressure; TAPSE = tricuspid annular plane systolic excursion.

positive results, increasing the number of patients to be referred for an invasive diagnostic procedure and, consequently, increasing the costs and associated risks.

TAPSE/sPAP ratio < 0.55 mm/mm Hg showed better diagnostic performance than sPAP > 36 mm Hg. Moreover, TAPSE/sPAP ratio was the parameter with the highest specificity. The probability of a TAPSE/sPAP ratio ≥ 0.55 mm/mm Hg correctly identifying non-PH patients with SSc was 78.9%. The higher specificity decreases the number of false positives, reducing unnecessary RHC. This high specificity was at the expense of a quite low sensitivity. Moreover, the TAPSE/sPAP ratio PPV was significantly higher than the PPV of all the other considered parameters. Among patients with SSc who had a TAPSE/sPAP ratio < 0.55 mm/mm Hg, the probability of PH was 50%. The DETECT study reported a PPV of 35% with the DETECT algorithm.⁹ In a previous study, we compared the TAPSE/sPAP ratio PPV and the DETECT algorithm PPV in 51 patients with SSc: the PPV of the TAPSE/sPAP ratio was higher than the PPV of the DETECT algorithm (62.5% vs 31.3%).¹⁷ Hao and colleagues¹⁸ compared the predictive accuracy of three screening models in 73 patients with SSc (DETECT vs Australian Scleroderma Interest Group [ASIG] vs 2009 ESC/ERS). The reported PPV for the three algorithms was between 55% and 60%. With PH prevalence set at 10%, the PPV was less than 20%. All the aforementioned studies defined PH as an mPAP ≥ 25 mm Hg. Cieurzyński and colleagues¹⁹ demonstrated that sPAP has the highest area under the curve between resting and exercise echo Doppler parameters. Doppler resting and exercise echocardiography may provide a reliable, noninvasive method for determining resting and exercise sPAP, mPAP, and PVR in patients with SSc. In our study, TAPSE/sPAP ratio was also the parameter with the highest accuracy among the considered parameters. The overall probability of TAPSE/sPAP ratio < 0.55 mm Hg correctly identifying patients with SSc with mPAP 21 to 24 mm Hg (true positives) and patients with mPAP < 20 mm Hg (true negatives) was 68.1%.

Therefore, we can assume that a Dlco < 80% of the predicted value is the most reliable parameter to minimize the number of missed PH diagnoses in patients with SSc with mPAP 21 to 24 mm Hg, and that the TAPSE/sPAP ratio can be a useful additional parameter in association with the Dlco for identifying patients who should be referred to RHC and reducing

661 the number of unnecessary invasive diagnostic
662 procedures.
663
664 This is, to our knowledge, the first study that attempts to
665 redefine the screening approach in the specific subsets of
666 patients with SSc with mild PH. Echocardiography
667 combined with other tests (BNP/NT-proBNP, PFTs,
668 serum urate) is recommended as a screening test in
669 asymptomatic patients with SSc, followed by annual
670 assessments.⁴

671 However, the study has some limitations. Patients
672 were selected on the basis of available TAPSE,
673 sPAP, and mPAP data. Many data were missing for
674 parameters included in the DETECT algorithm, in
675 particular TRV and RAA, so that comparing the
676 diagnostic performance of TAPSE/sPAP ratio and
677 the DETECT algorithm was not possible. Some RHC
678 data were missing (pulmonary arterial wedge
679 pressure and pulmonary vascular resistance), so that
680 defining the PH group was not possible for all
681 patients included. Although patient selection was
682 based on available data and many RHC data were
683 missing in the EUSTAR database, the results are
684 generalizable and applicable to the general
685 population because they are based on cutoffs of
686 parameters established by the ESC/ERS guidelines.
687 In addition, the imputation confirms the data
688 present in the EUSTAR register.

692 Interpretation

693 In conclusion, DLCO < 80% of the predicted value is the
694 parameter with the highest sensitivity and NPV in
695
696

698 Acknowledgments

699 Author contributions:

700 ***EUSTAR Collaborators:** Oliver Distler
701 (Zurich, Switzerland), Mike Becker (Zurich,
702 Switzerland); Melissa De Decker (Ghent,
703 Belgium); Danilo Alunni Fegatelli (Rome,
704 Italy); Elise Siegert (Berlin, Germany); Ivan
705 Castellví (Barcelona, Spain); Alberto Cauli
706 (Monserrato, Italy); Kamal Solanki
707 (Hamilton, New Zealand); Lorenzo Dagna
708 (Milan, Italy); Mickaël Martin (Poitiers,
709 France); Gianluca Moroncini (Ancona, Italy);
710 Hadi Poormoghim (Tehran, Iran); Masataka
711 Kuwana (Tokyo, Japan); Patricia E. Carreira
712 (Madrid, Spain); Paolo Airò (Brescia, Italy);
713 Christina Bergmann (Erlangen, Germany);
714 Julia Spierings (Utrecht, The Netherlands);
715 Yoshiya Tanaka (Kitakyushu, Japan); Enrico
Selvi (Siena, Italy); Tomas Soukup (Hradec
Kralove, Czech Republic).

716 detecting patients with SSc with mPAP 21 to 24 mm Hg.
717 TAPSE/sPAP < 0.55 mm/mm Hg has the highest
718 specificity, PPV, and accuracy and, therefore, can be a
719 useful additional parameter to decrease the number of
720 unnecessary RHCs.
721

722 Funding/Support

723 This research did not receive any specific grant from
724 funding agencies in the public, commercial, or not-for-
725 profit sectors.
726

727 Financial/Nonfinancial Disclosures

728 The authors have reported to *CHEST* the following: V. S.
729 is senior clinical investigator of the Research
730 Foundation—Flanders (Belgium): (FWO) (1.8.029.20N).
731 This funding source had no role in the literature review
732 and the synthesis and interpretation of the data; in the
733 writing of the report; or in the decision to submit the
734 paper for publication. C. B. received grants from
735 Boehringer-Ingelheim, consulting fees from Janssen,
736 honoraria for lectures from Novartis, and travel grants
737 from Kyverna, which were not related to this project; E.
738 Z. received speaking and lecture fees from Janssen and
739 consulting fees from Janssen and GSK; F. I. received
740 honoraria and speaking fees from AbbVie, Eli Lilly,
741 Galapagos, Janssen, Novartis, Pfizer, and UCB outside
742 this work; C. P. S. A. received consulting fees and support
743 for attending meetings from Janssen-Cilag SAS,
744 Boehringer Ingelheim Ltd and MSD. None declared (A.
745 C., E. H., C. P., G. R., J. H., D. L., A. M., A. M. G., M.-E.
746 T., S. O., M. V., F. D. G., E. R.).
747
748
749
750
751

752 References

- 753 1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS); endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2016;37(1):67-119. 754
- 755 2. Assad TR, Maron BA, Robbins IM, et al. Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension. *JAMA Cardiol*. 2017;2(12):1361-1368. 755
- 756 3. Maron BA, Hess E, Maddox TM, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. *Circulation*. 2016;133(13):1240-1248. 756
- 757 4. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022;43(38):3618-3731 [published correction appears in *Eur Heart J*. 2023;44(15):1312]. 757
- 758 5. Bruni C, De Luca G, Lazzaroni MG, et al. Screening for pulmonary arterial hypertension in systemic sclerosis: a systematic literature review. *Eur J Intern Med*. 2020;78:17-25. 758
- 759 6. Colalillo A, Hoffmann-Vold AM, Pellicano C, et al. The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the 759

771	systemic sclerosis EUSTAR cohort.		
772	<i>Autoimmun Rev.</i> 2023;22(4):103290.		
773	7. Steen V, Medsger TA Jr. Predictors of		
774	isolated pulmonary hypertension in		
775	patients with systemic sclerosis and		
776	limited cutaneous involvement. <i>Arthritis</i>		
777	<i>Rheum.</i> 2003;48(2):516-522.		
778	8. Allanore Y, Borderie D, Avouac J, et al.		
779	High N-terminal pro-brain natriuretic		
780	peptide levels and low diffusing capacity		
781	for carbon monoxide as independent		
782	predictors of the occurrence of		
783	precapillary pulmonary arterial		
784	hypertension in patients with systemic		
785	sclerosis. <i>Arthritis Rheum.</i> 2008;58(1):		
786	284-291.		
787	9. Coghlan JG, Denton CP, Grünig E, et al.		
788	Evidence-based detection of pulmonary		
789	arterial hypertension in systemic sclerosis:		
790	the DETECT study. <i>Ann Rheum Dis.</i>		
791	2014;73(7):1340-1349.		
792	10. Thakkar V, Stevens WM, Prior D, et al. N-		
793	terminal pro-brain natriuretic peptide in a		
794	novel screening algorithm for pulmonary		
795	arterial hypertension in systemic sclerosis:		
796	a case-control study. <i>Arthritis Res Ther.</i>		
797	2012;14(3):R143.		
798			
799			
800			
801			
802			
803			
804			
805			
806			
807			
808			
809			
810			
811			
812			
813			
814			
815			
816			
817			
818			
819			
820			
821			
822			
823			
824			
825			
	11. Williams MH, Handler CE, Akram R,		
	et al. Role of N-terminal brain natriuretic		
	peptide (N-TproBNP) in scleroderma-		
	associated pulmonary arterial		
	hypertension. <i>Eur Heart J.</i> 2006;27(12):		
	1485-1494.		
	12. Elhai M, Meune C, Boubaya M, et al.		
	Mapping and predicting mortality from		
	systemic sclerosis. <i>Ann Rheum Dis.</i>		
	2017;76(11):1897-1905.		
	13. Meier FM, Frommer KW, Dinser R, et al.		
	Update on the profile of the EUSTAR		
	cohort: an analysis of the EULAR		
	Scleroderma Trials and Research group		
	database. <i>Ann Rheum Dis.</i> 2012;71(8):		
	1355-1360.		
	14. van den Hoogen F, Khanna D,		
	Fransen J, et al. 2013 classification		
	criteria for systemic sclerosis: an		
	American College of Rheumatology/		
	European League against Rheumatism		
	collaborative initiative. <i>Arthritis Rheum.</i>		
	2013;65(11):2737-2747.		
	15. Hachulla E, Clerson P, Airò P, et al. Value		
	of systolic pulmonary arterial pressure as a		
	prognostic factor of death in the systemic		
	sclerosis EUSTAR population.		
	<i>Rheumatology (Oxford).</i> 2015;54(7):	826	
	1262-1269.	827	
	16. McDonagh TA, Metra M, Adamo M, et al;	828	
	ESC Scientific Document Group. 2021	829	
	ESC guidelines for the diagnosis and	830	
	treatment of acute and chronic heart	831	
	failure. <i>Eur Heart J.</i> 2021;42(36):	832	
	3599-3726.	833	
	17. Colalillo A, Grimaldi MC, Vaiarello V,	834	
	et al. In systemic sclerosis, the TAPSE/	835	
	sPAP ratio can be used in addition to the	836	
	DETECT algorithm for pulmonary	837	
	arterial hypertension diagnosis.	838	
	<i>Rheumatology (Oxford).</i> 2022;61(6):	839	
	2450-2456.	840	
	18. Hao Y, Thakkar V, Stevens W, et al.	841	
	A comparison of the predictive accuracy	842	
	of three screening models for	843	
	pulmonary arterial hypertension in	844	
	systemic sclerosis. <i>Arthritis Res Ther.</i>	845	
	2015;17(1):7.	846	
	19. Ciuzyński M, Bienias P, Ciesielska K,	847	
	et al. Accuracy of Doppler	848	
	echocardiography in the hemodynamic	849	
	assessment of pulmonary circulation in	850	
	patients with systemic sclerosis. <i>Adv Med</i>	851	
	<i>Sci.</i> 2019;64(2):309-314.	852	
		853	
		854	
		855	
		856	
		857	
		858	
		859	
		860	
		861	
		862	
		863	
		864	
		865	
		866	
		867	
		868	
		869	
		870	
		871	
		872	
		873	
		874	
		875	
		876	
		877	
		878	
		879	
		880	